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Milrinone is a new bipyridine inotrope that has shown
promise in initial clinical testing when administered in-
travenously or orally. The present multicenter study was
designed to evaluate the clinical effectivenessand safety
of sustained (48 hour) intravenous infusions of different
doses of milrinone, as would be used clinically, in a
controlled fashion using invasive hemodynamic moni-
toring. Entry was limited to adult patients with chronic
heart failure of functional class IIIor IV, with a cardiac
index ::0;2.5 liters/min per m2 or a pulmonary capillary
wedge pressure ~15 mm Hg, or both. After stable base-
line hemodynamic recordings were obtained, milrinone
was givenas loading (lLg/kg per 10min) and maintenance
infusions (lLg/kg per min) to 189 patients in one of four
loading/maintenance dosage regimens: 37.5/0.375 (low
dose, n = 26), 50/0.50 (intermediate dose, n = 95),
75/0.75 (high dose, n = 15) and 50/0.25 (lowest dose, n
= 53).
The lowest dose was shown to be ineffectivefor main-
tenance therapy. Effective individual patient responses
were defined as ~20% increase in cardiac index or de-
crease in pulmonary capillary wedge pressure, or both.
During early therapy (-0;3 hour), 99% of patients showed
an effective maximal response, and 90% an effective
mean response. An effective mean response was ob-
served during days I and 2 in 80% of patients, with a
positive dose-response trend (69% response, low dose;
80%, intermediate dose; 93%, high dose; day I). Each
loading regimen was effective, with maximal mean re-
Congestive heart failure is a major medical problem that is
growing in importance, affecting more than 3 million Arner-
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sponse occurring at 15 minutes. Cardiac index initially
increased by an average of 24 to 42% for all patients in
the three groups, whereas pulmonary capillary wedge
pressure decreased by 24 to 33%. Initial decreases in
systemic vascular resistance averaged 15 to 31%. Initial
changes in heart rate (+4 to +13%) and mean arterial
pressure (- 2 to -13%) were modest. Significant mean
hemodynamic responses were maintained over the 48
hours. Increases in cardiac index for days 1 and 2 av-
eraged 38 and 39% for those completing constant low
dose drug, 34 and 37% for intermediate dose and 73
and 44% for high dose. Decreases in pulmonary capil-
lary wedge pressure for all patients averaged 18 to 32%
on days I and 2, with little dose response. Heart rate
changes were modest and variable, averaging - 9 to 9%.
Mean arterial pressure decreased slightly (2 to 6%) for
the lower doses and moderately (8 to 16%) for the high
dose. Reductions in systemic vascular resistance aver-
aged 20 to 25%. Calculated stroke work index remained
substantially augmented (21 to 58%).
Milrinone was well tolerated: sustained ventricular
tachycardia occurred in only one patient (0.5%) and
thrombocytopenia was not problematic. Thus, mdrtnone
infusions of 0.375 to 0.75 ILg/kg per min are associated
with an excellent rate of hemodynamic response that is
maintained for at least 48 hours, and with generally
excellent safety and tolerance in patients with advanced
chronic heart failure.
(J Am Coil CardioI1987;9.·71J-22)
icans (I). It is a physically debilitating disease with a poor
prognosis which presents therapeutic challenges for control
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of both its acute and chronic manifestations (2-8). The
medical treatment of congestive heart failure has passed
through several stages, beginning with the application of
digitalis glycosides in 1785 (9), the development of potent
diuretics (8) and more recently the introduction of vasodi-
lators (10). However, substantial deficiencies still exist in
pharmacotherapy for severely ill patients. Attention is cur-
rently focused on the therapeutic potential of a variety of
inotropic agents (11).
Dobutamine, a relatively cardioselective beta-j-receptor
agonist, has enjoyed widespread use in the short-term man-
agement of severe congestive heart failure (12,13). How-
ever, catecholamines (dopamine, dobutamine, and so on)
have the potential for arrhythmogenesis and the develop-
ment of tolerance (14-17) and do not have orally effective
analogues. Amrinone, recently approved for the intravenous
therapy of congestive heart failure, is the prototype of a
new group of nonsympathomimetic, nonglycoside, ino-
tropic agents that inhibit cardiac phosphodiesterase
(11,18-24). However, amrinone has not proved effective
for long-term oral therapy because of an unacceptable side
effect profile (21-23).
Milrinone is a bipyridine methyl carbonitrile analogue of
amrinone possessing 10 to 30 times greater potency and
fewer adverse effects in experimental studies to date (25-50).
Milrinone causes both prominent inotropic and vasodilator
responses (41,42), and improves cardiac diastolic perform-
ance (36). It favorably affects myocardial energetics, im-
proving cardiac performance without increasing myocardial
oxygen consumption (40,44).
Interest in the further development of milrinone has been
raised by favorable initial intravenous (single dose or short-
term) and oral studies in humans (25-27,31-40,43-45).
When intravenous inotropic therapy is applied in the clinical
setting of heart failure, prolonged infusions are usually re-
quired (?: I to 2 days). The assessment of intravenous mil-
rinone for clinical application requires longer-term, con-
trolled studies to define safety, efficacy and maintenance
dosing requirements. Thus, the present study was designed
to evaluate sustained (48 hour) intravenous infusions of
milrinone in a controlled fashion using invasive hemody-
namic monitoring.
Methods
The study was designed as a phase III multicenter efficacy
and safety trial of sustained (48 hour) intravenous milrinone
therapy, given as a loading injection and maintenance in-
fusion to hospitalized patients with advanced heart failure.
Approval was obtained from each Institutional Review Board
before initiation of the study. Written informed consent was
required of each patient before study entry.
Eligibility and exclusion. Adults with stable (>2 weeks)
New York Heart Association functional class III or IV
congestive heart failure were candidates for the study.
Hemodynamic requirements included cardiac index :::::2.5
liters/min per nr' or pulmonary capillary wedge pressure
?:15 mm Hg, or both. Women were required to be post-
menopausal or surgically sterile to be eligible.
Patients were excluded for radionuclide ejection fraction
>40%, symptomatic primary pulmonary disease, primary
liver disease, severe renal impairment (creatinine >3 mg/dl),
platelet count <120,OOOIJ.t1, unstable angina, myocardial
infarction within 3 months, heart failure in association with
uncorrected native or artificial valve disease, obstructive
cardiomyopathy, thyroid disease, amyloid cardiomyopathy,
untreated ventricular tachycardia of more than six beats'
duration and sudden death syndrome or ventricular fibril-
lation (except during or immediately after an acute infarc-
tion). Concomitant or previous bipyridine therapy formed
an additional exclusion.
Patient entry characteristics. The study group con-
sisted of 189 patients entered at 13 study sites. (Six addi-
tional patients were screened and entered but later excluded
because of failure to satisfy hemodynamic entry criteria.)
The group was 79% male and averaged 57.3 years of age
(range 18 to 80). The origin of heart failure was ischemic
in 47% (44% with previous myocardial infarction), dilated
cardiomyopathy in 43% and valvular disease in 7%; 27%
had undergone prior cardiac surgery. Patients were equally
divided among those of New York Heart Association func-
tional class III (51%) and IV (49%). Left ventricular ejection
fraction averaged 17.3 ± 0.5% (mean ± SEM). Distri-
butions of individual entry characteristics did not differ sig-
nificantly by assigned dosage regimen.
Previous medications included digitalis in 95%, diuretics
in 100%, antiarrhythmic agents in 42% and vasodilators in
82%. During the study, concurrent medications were: dig-
italis (primarily digoxin), 77%; diuretics (primarily furo-
semide), 88%; antiarrhythmic agents (usually procainamide
or quinidine), 44% and vasodilators (for non-heart failure
indications, primarily nitrates), 28%.
Study treatment plan. The multicenter investigation
was an open label comparative study of multiple intravenous
doses of milrinone, administered by both loading injection
and continuous infusion, in the treatment of patients with
heart failure. A placebo-controlled substudy was also in-
cluded.
Pre- and poststudy evaluations. Complete medical his-
tory, physical examination and laboratory and electrocar-
diographic evaluations were performed within 48 to 72 hours
and chest X-ray film and radionuclide ejection fraction within
14 days before drug therapy. Laboratory tests and clinical
evaluations were repeated within 24 hours after termination
of milrinone therapy.
Hospitalization/baseline measurements. Patients were
admitted to the cardiac intensive care unit and monitored
there for the entire duration of the study. Captopril therapy
(if used) was discontinued at least 24 hours before drug
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administration but doses of other cardiac medications re-
mained constant. A flow-directed, balloon-tipped (Swan-
Ganz) catheter was placed by standard technique using the
subclavian, internal jugular, brachial or femoral approach.
Arterial pressures were measured directly through a radial
artery cannula or by blood pressure cuff. Hemodynamics
were allowed to stabilize after placement of monitoring lines.
Recordings of baseline hemodynamic measurements were
then performed at least 10 minutes apart and within I hour
before drug administration. Two consecutive measurements
for either cardiac output or meanpulmonary capillary wedge
pressure fell within the designated 15% of each other for
all but 2 of the 189 patients analyzed.
Drug administration regimens. After meeting baseline
hemodynamic criteria, rnilrinone was administered as a
loading injection followed by a continuous infusion. Dose
regimens were assigned in a prospective (although nonran-
domized) fashion. Injection doses ranged from 37.5 to 75
J-Lg/kg, given over 10 minutes, and maintenance infusion
doses from 0.25 to 0.75 J-Lg/kg per min, infused for 48
hours. The dose regimens wereassigned to definea spectrum
within the expected range of drug efficacy. The specific
regimens used, describedas loading/maintenancedosage (in
J-Lg/kg and J-Lg/kg per min) were: 37.5/0.375 (n = 26):
50/0.50 (n = 95); 75/0.75 (n = 15)and 50/0.25 (n = 53).
Adjustment downward or discontinuation of dose was per-
mitted in the event of a clinically significant adverse reaction
potentially relatedto the drug, and blood was simultaneously
sampled for milrinone concentration.
Monitoring therapeutic response. Hemodynamic mea-
surements using the right heart catheter were made at the
following times after initiation of therapy: 5, 15 , 30 and 45
minutes and I, 3, 6, 12, 18, 24, 30, 36, 42 and 48 hours.
In 10 patients on the 0.50 J-Lg/kg per min infusion regimen,
5 ml blood samples for plasma milrinone determinations
were taken within 10 minutes of initiation (control) and
within5 minutes of each hemodynamic determination, from
a site distant from that used for drug infusion.
For each time point, the f ollowing variables were re-
corded: cardiac output by the thermodilution method, mean
pulmonary capillary wedge pressure, systemic arterial pres-
sure, mean pulmonary artery pressure, mean right atrial
pressure and heart rate. Derived variables included cardiac
index, systemic vascular resistance, pulmonary vascular re-
sistance, stroke volume, stroke volume index and stroke
work index.
Placebo-controlled substudy. To determine the initial
hemodynamic effects of placebo, and compare this with
rnilrinone , 31 patients from three centers entered a triple-
blind comparison of milrinone, a 50.0 J-Lg/kg loading in-
jection followed by a 0.50 J-Lg/kg per min continuous in-
fusion, and matchingplacebo. Hemodynamic measurements
were made at baseline and at 5, 15,30,45 and 60 minutes.
The treatment code was broken after I hour of therapy and
open label milrinone was given to both the active treatment
and the placebo groups for 48 hours.
There was no difference in baseline variables in patients
randomized to placebo (n = 15) or milrinone therapy (n
= 16). Demographic comparisons included age, weight,
sex, New York Heart Association heart failure class and
etiology of heart failure. Baseline hemodynamic variables
measured as already defined were also comparable between
the two groups.
Statistical considerations. Three basic analytical ap-
proaches were used: I) evaluation of the time course of
hemodynamic response (for all patients); 2) determination
of mean values of hemodynamic response partitioned into
initial (15 minutes, the time of expected maximal effect),
early (mean of measurements recorded for IS minutes through
3 hours). day 1 (mean values for 6 through 24 hours) and
day 2 responses (mean of determinations for 30 through 48
hours); and 3) distribution of individual hemodynamic re-
sponses (to assess individual patient response profiles). An
effective individual response was defined as an increase
2:20% in cardiac index or a fall 2:20% in pulmonary cap-
illary wedge pressure. or both. The rationale for the time
partitions derived from a two compartment model of mil-
rinone pharmacokinetics (distribution and elimination half-
lives of 6.1 minutes and 2.6 ± 0.2 hours, respectively) and
clinical goals, that is, to rapidly achieve and then maintain
a beneficial response. The three constant dosage regimens
(37.5/0.375, 50/0.50 and 75/0.75 J-Lg/kg and J-Lg/kg per min,
respectively) were compared using analysis of variance and
analysis of covariance for all of the individual variables.
Changes in other hemodynamic variables and laboratory
measurements were also analyzed and compared with base-
line values. using parametric and nonparametric methods.
Evaluation was made of the hemodynamic response for all
patients (n = 189) and for patients actually completing
assigned treatment without dose adjustment (n = 112).
Conclusions did not differ between the two analyses. Data
are expressed as mean ± SEM.
Results
Baseline hemodynamic characteristics. Mean baseline
hemodynamic data for the entire study group included the
following : cardiac index, 1.98 ± 0.04 liters/min per m2;
mean pulmonary capillary wedge pressure, 26.3 ± 0.6 mm
Hg; mean arterial pressure, 82.5 ± 1.0 mm Hg; heart rate,
89.3 ± 1.1 beats/min; stroke volume index. 22.9 ± 0.6
ml/rrr' : and systemic vascular resistance, 1691 ± 48
dynes-s-cm . 5 . Baseline hemodynamic characteristics did
not differ signifi cantly among patients subgrouped by as-
signed dosage regimen.
Responses to milrinone loading injections (Tables 1
and 2, Fig. 1 to 3). The effect of the 10 minute milrinone
loading injection was rapid, the maximal group changes in
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Table 1. Comparison of Early (0 to 6 hours) Responses to
Lowest Versus Intermediate Dose Maintenance Regimen:
Comparison of Mean Percent Changes From Baseline in
Selected Variables
Regimen (injection dose
IJLg/kg]linfusion dose
IJLg/kg per min]) (%)
Lowest Intermediate
Variable/Time Maintenance Maintenance
Interval (50.0/0.25) (50.0/0.50)
(hours) (n = 53) (n = 95)
Cardiac index
o to I (max) 44.8 56.4
I (mean) 28.9 36.8
3 (mean) 16.4** 35.2
6 (mean) 15.3** 38.0
Pulmonary capillary
wedge pressure
o to I (max) -38.8 -36.7
I (mean) -23.9 -22.7
3 (mean) -16.5 -23.8
6 (mean) -8.7* -22.2
Heart rate
o to I (max) 7.0 9.0
I (mean) 2.8 4.0
3 (mean) 1.8 2.5
6 (mean) 2.1 3.4
Mean arterial pressure
o to 1 (max) -10.8 -8.5
I (mean) -5.1 -3.6
3 (mean) -4.1 -7.0
6 (mean) - 3.4* -7.7
Stroke volume index
o to I (max) 41.2 51.5
I (mean) 25.5 32.4
3 (mean) 14.8** 33.3
6 (mean) 15.4** 36.0
System vascular resistance
o to I (max) -30.0 -33.1
I (mean) -19.7 -21.3
3 (mean) - 9.2** -22.8
6 (mean) -9.5** -24.2
Stroke work index
o to I (max) 51.5 64.4
I (mean) 29.8 40.0
3 (mean) 20.3* 34.6
6 (mean) 17.8** 37.2
'p < 0.05; "p < 0.01 for interdose comparison.
hemodynamic variables being observed at 15 minutes after
the start of the infusion. Each milrinone loading injection
dose effected significant increases in group mean cardiac
index and stroke volume index, averaging 24 to 42% for
cardiac index for the different groups at 15 minutes. This
response was accompanied by decreases in group mean pul-
monary capillary wedge pressure (averaging 24 to 33%) and
systemic vascular resistance (averaging 15 to 31%). In-
creases in heart rate and decreases in mean arterial pressure
were modest. The mean group increases in calculated stroke
work index averaged 18 to 52%. The trends in cardiac index
and stroke volume index suggested a dose-response relation
for loading dose increments of 37.5 to 50 but not for 50 to
75 j.tg/kg. No interdose comparisons reached significance,
however.
Response to placebo versus milrinone (Table 3, Fig.
4). There were highly significant differences between pla-
cebo and milrinone treatments during the 1 hour comparison
of hemodynamic responses in the placebo versus milrinone
substudy. No significant placebo group response occurred
in any hemodynamic variable. In contrast, the milrinone
group experienced mean increases in cardiac index, stroke
volume index and stroke work index (of 41, 32 and 35%,
respectively), and decreases in pulmonary capillary wedge
pressure, systemic vascular resistance and mean arterial
pressure (of 25, 24 and 5%, respectively). Differences be-
tween the milrinone and placebo responses were highly sig-
nificant.
Patients who received placebo during the first hour sub-
sequently responded in the expected fashion to milrinone
given during the second hour, as shown by changes in hemo-
dynamic variables. Thus, hemodynamic changes observed
were shown to result from milrinone therapy and not from
a placebo effect. Individual placebo-associated changes in
hemodynamic variables representing 2 SO about the norm
(85% confidence intervals) included changes in cardiac in-
dex less extreme than increases of 17. I% and changes in
pulmonary capillary wedge pressure less extreme than de-
creases of 19.1%. Thus, increases 2':20% in individual mea-
surements of cardiac index and decreases 2':20% in pul-
monary capillary wedge pressure, defined as representing
clinically effective individual changes, were also likely sta-
tistically to represent true drug rather than placebo effects.
Early «6 hours) postloading responses to lowest dose
(0.25 ltg/kg per min) milrinone infusions (Table 1). The
constant milrinone infusions provided early maintenance of
the significant responses to drug loading during the subse-
quent 3 to 6 hours for all but the 0.25 /Lg/kg per min infusion
rate. After an equivalent response to the 50 /Lg/kg per 10
min loading injection, hemodynamic responses differed sig-
nificantly at 3 to 6 hours for the lowest maintenance infusion
rate (0.25 /Lg/kg per min) compared with 0.50 j.tg/kg per
min, the intermediate (mode) infusion dose. The divergence
of cardiac index response by 3 to 6 hours was significant,
with mean increases at 6 hours averaging only 15% for the
0.25 /Lg/kg per min dose versus 38% for the 0.50 j.tg/kg
per min dose (p < 0.01). Corresponding changes for stroke
volume index were 15 versus 36% at 6 hours (p < 0.01).
Changes in pulmonary capillary wedge pressure were also
attentuated at 6 hours for the lowest dose regimen (- 9
versus - 22% change, p < 0.05). Reductions in systemic
vascular resistance differed at 3 and 6 hours ( - 10 versus
-24% change, p < 0.01, 6 hours), and the reduction in
mean arterial pressure was less at 6 hours (- 3.4 versus
JACC Vol. 9. No.4
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Table 2. Comparison of Time-Partitioned Mean Hemodynamic Responses to Three Different
Dosage Regimens: Mean Percent Change From Baseline (adjusted for center differences)
Regimen (injection dose liLg/kg]linfusion dose liLg/kg per min])
37.5/0.375* 50/0.50* 75/0.75*
Variable/Time
Interval n = 25t n = 26t n = 80t n = 95t n = 7t n = 1St
Cardiac index
Initial (15 min) 32.8 24.0 47.7 42.1 56.0 34.0
Day It 38.2 34.3 34. 1 35.9 73. 1 34.3
Day 2§ 38.9 34.3 36.6 38.7 43.9 20.7
Pulmonary capillary
wedge pressure
Initial (15 min) -27.0 -23.7 - 28.8 - 27.6 - 3 \. 9 -33.0
Day It - 23.3 - 23.4 - 21.2 - 20.0 - 10.3 - 3 \.8
Day 2§ - 21.7 - 23.2 - 21.4 - 18.0 - 24.7 - 18.6
Heart rate
Initial (15 min) \.9 3.7 3.5 4.8 11.7 13.3
Day It 7.9 6. 1 2.2 \.6 5.3 7.1
Day 2§ 8.5 10.6 4 .9 4.9 - 8.8 2.9
Mean arterial pressure
Initial (15 min) - \. 8 -4.1 - 2.3 -2. 1 - 0.7 - 12.5
Day It -6.2 - 8.3 -4.5 -6.0 -1 6.4 -1 8.1
Day 2§ -3.8 - 3.8 - 2.3 -3.8 -7.5 -9.7
Stroke volume index
Initial (15 min) 30.7 19.8 44.0 36.6 42.8 19.7
Day It 28.8 27.8 32.5 35.7 69.7 27.0
Day 2§ 28.9 22.3 31.3 33.3 61.1 19.1
System vascular resistance
Initial (15 min) -1 7.0 - 14 .7 -27 .2 - 2 \. 9 - 27.3 - 31.4
Day It -22. 1 - 25.1 -2 \.9 -22. 1 - 24 .6 -35.2
Day 2§ - 22.0 - 22.0 -1 9.6 -22.6 - 22.6 -25.4
Stroke work index
Initial (15 min) 32.9 17.5 60. 1 52.3 58.7 3 \. 4
Day It 20.5 16. 1 39.4 37.5 58. 1 30.4
Day 2§ 3 \. 5 26.8 35.9 34.4 46.2 26.1
'Values to the left of the shill are iLg/kg; to the right of the shill are iLg/kg per min. t First and second
values under each regimen are number of patients on constant infusion regimen and total number of patients,
respectively. Some minor variations in n occur for individual measurements, due to sporadic missing values.
t 6 to 24 hours. §30 to 48 hours. No parallel interdose comparisons reached statistical significance.
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- 7.7% change , p < 0.05) . Augmentatio n in stroke work
index was significantly less at 3 and 6 hours for the lowest
dose regimen (18 versus 37%, p < 0.0 1, 6 hours).
Because of the early inefficacy of milr inone infusions of
0.25 ,ug/kg per min. pat ients assigned to this dose were
crossed over to the 0.50 ,ug/kg per min infusion rate at 6
hours . Their subsequent hemodynamic data are not included
in later efficacy analyses.
Responses During Chronic Maintenance (6 to 48
hours) Milrinone Infusions (Table 2, Fig . I to 3).
Hemodynamic responses were generally maintained dur-
ing maintenance milrinone infusions of O.375 to 0.75 j.Lg/kg
per min and were relatively constant from postloading (about
3 hours) to end of infusion (48 hours). with some variations .
Group response of cardiac index and stroke volume
index (Table 2, Fig. 1 to 3). Time-partitioned mean re-
sponses of cardiac index and stroke volume index, compared
with baseline, for the range of maintenance infusion doses
(0.375 = low dose , 0.50 = intermediate dose and 0.75
,ug/kg per min = high dose) are presented in Table 2.
Results are presented by the initiall y assigned dose regimen
both for patie nts receiving the given dose continuously
(without modification) throughout the 48 hour observation
period ("constant regimen " ) and for all patients initially
assigned to that dose , including those with a later downward
dose adjustment. Figure I shows the time-related changes
in absolute values for cardiac index for the three doses.
(Temporal changes in stroke volume index , not shown , par-
allel cardiac index because heart rate rema ined relatively
constant.) Results in Figures I to 3 are presented for patients
rece iving a constant dose throughout; time-related results
for all patients (not show n) were similar.
Increases in card iac index were maintained through day
I and day 2 for those treated constantly with low dose (38
and 39% for days I and 2), intermediate dose , (34 and 37%,
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Figure 1. Temporal response of mean cardiac index for the three
constant dosing regimens during the study. Results represent pa-
tients receiving a constant infusion dose throughout (0.375 /Lg/kg
per min, n = 25; 0.50 /Lg/kg per min, n = 80; 0.75 /Lg/kg per
min, n = 7). Data are given as mean ± SEM.
respectively) and high dose (73 and 44%). Absolute re-
sponse for cardiac index appears to be greater than expected
for the high dose regimen because of the higher baseline
cardiac index and stroke volume index in this group. The
greater variability in response during high dose infusion is
explained by the small number of continued patients (n =
7).
Group responses of mean pulmonary capillary wedge
pressure (Table 2, Fig. 2). Time-partitioned mean re-
sponses for pulmonary capillary wedge pressure by dose are
Figure 2. Temporal responseof mean pulmonary capillarywedge
pressure (PCWP) for the three constant dosing regimens during
the study. See legend to Figure I for additional information.
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Figure 3. Temporal response of mean arterial pressure (MAP)
(above) and mean systemic vascularresistance (SVR) (below) for
the three constant dosing regimens during the study. See legend
to Figure I for additional information.
also presented in Table 2 and Figure 2 shows the time-
related changes in absolute pulmonary capillary wedge pres-
sure for the three doses. Responses of pulmonary artery
pressure and right atrial pressure (not presented) were gen-
erally similar. Mean pulmonary capillary wedge pressure
decreased by 21 to 23% for low and intermediate doses,
and responses were similar for initial, day I and day 2
measurements. Changes were generally similar but more
variable for the small number in the high dose group.
Individual responses of cardiac index and pulmonary
capillary wedge pressure. Responses in an individual pa-
tient considered to be clinically effective were defined as
increases in cardiac index ~20% or decreases in pulmonary
lACC Vol. 9. No.4
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Table 3. Comparison of Hemodynamic Responses to Placebo and Milrinone
Baseline Measures (mean ::!: SEM) and Percent Change From Baseline Regimen
(injection dose [j.lg/kg]linfusion dose lj.lg/kg per rnin l)
Milrinone , first hour Milrinone , second hour
(50.0/0.50) Placebo. first hour (placebo group)
Variable/Time Interval (n = 16) (010) (n = IS) (50.0/0.50) (n = 15)
Cardiac index
Baseline (liters/min per m2) 2.11 ::!: 0.18 2.05 ::!: 0.11
IS Min (a) (%) 47.1 *** 1.2 *** 43.3
60 Min (a) (%) 38.9 *** - 10.8 *** 29.4
Mean (5 to60 min) (a) (%) 40.8 *** - 2.6 *** 32.3
Pulmonary capillary wedge pressure
Baseline (mm Hg) 26.3 ::!: 1.4 22.6 ::!: 1.3
15 Min (a) (%) -28.5 ** - l.8 *** - 37.9
60 Min (a) (%) -22. 1 - 8 5 ** - 31.4
Mean (5 to60 min) (a) (%) -25.0 * -4.7 *** -30.5
Heart rate
Baseline (beats/min) 86.6 ::!: 5.1 92.1 ::!: 2.8
IS Min (a) (%) 10.0 4.6 8.0
60 Min (a) (%) 5.8 2.8 4.1
Mean (5 1060 min) (al (%) 7.2 2.8 6.4
Mean arterial pressure
Baseline (mm Hg) 83.4 ::!: 3.l! 83.2 :!: 5.0
15 Min (a) (%) -3.7 - 0.2 -3 .5
60 Min (a) (%) - 8. 1 ** 2.4 -3 .5
Mean (5 to60 min) (a) (%) -4.9 0 .1 -3 .0
Stroke volume index
Baseline (rnl/beat per rrr') 25.2 ::!: 2.4 22.6 ::!: 1.3
15 Min (a) (%) 33.5 ** - 2.7 *:ot:* 36.3
60 Min (a) (%) 31.3 *** - 11.5 *** 25.5
Mean (5 to60 min) (%) 31.5 *** - 4.3 *** 26.0
Systemic vascular resistance
Baseline (dynes-s-cm") 1.670 ::!: 143 1.614::!: 161
15 Min (a) (%) -25 .6 ** l.l *** -29.0
60 Min (a) (%) -26.7 ** 240 - 21.3
Mean (5 to 60 min) (%) -24. 1 *** 6.2 *** -2V\
Stroke work index
Baseline (g-rn/rrr') 20.7 ::!: 2.3 17.9 :!: 1.7
15 Min (M (%) 42.4 - 1.4 *** 48.7
60 Min (a) (%) 28.1 -5.8 ** 29.4
Mean (5 to60 min) (%) 34.7 ** -2.2 *** 34.5
*p oS 0.05; **p oS 0.01; ***p oS 0.001 for intergroup comparisons. A = change from baseline.
capillary wedge pressure of ~20% , or both, during a given
time period compared with baseline. The initial (15 minute)
response was clinically effective in virtually the entire group
of 134 patients (99%). During early therapy (S3 hours),
120 (90%) of the 134 patients responded. (Effective re-
sponses in cardiac index were maintained in 75%, and pul-
monary capillary wedge pressure in 57% of patients.) An
effective response was maintained during day I in 105 (80%)
of 132 patients. (Day I effective response rates for cardiac
index and pulmonary capillary wedge pressure were 66 and
56%, respectively.) Effective responses were maintained
during day 2 in 100 (79%) of 127 patients. (This included
effective day 2 responses for cardiac index in 70% and for
pulmonary capillary wedge pressure in 57%.) A trend in
the rates of clinically effective individual responses was
noted by infusion dose. with response rates for low, inter-
mediate and high doses of 69. 80 and 93% on day I, and
75. 79 and 86% on day 2. respectively.
Response of arter ial pressure, systemic vascular re-
sistance and heart rate (Table 2, Fig. 3). The time-
partitioned mean responses for mean arterial pressure. sys-
temic vascular resistance and heart rate for the range of
maintenance infusion doses are shown in Table 2 and the
time course of changes in absolute mean arterial pressure
and systemic vascular resistance for the three doses in Figure
3. A dose-response trend was noted for mean arterial pres-
sure changes: modest decreases of 2 to 6% were noted for
those maintained on constant infusions of low and inter-
mediate doses and greater decreases (of 8 to 16%) for those
maintained on high doses. A U-shaped temporal trend was
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Figure 4. Temporal response of cardiac index to placebo (n
15) and milrinone (n = 16) (50 JLg/kg per IO min, then 0.50
JLg/kg per min) . After I hour (dashed line), the placebo group
was crossed over to milrinone therapy. Data are given as mean
:t SEM.
noted for mean arterial pressure, with changes tending to
be greater on day I than either initially or on day 2 (sig-
nificant for low and high doses, days I versus 2). Reductions
in systemic vascular resistance of about 20 to 25% were
maintained for the three doses on both days I and 2. Heart
rate changed slightly and variably during maintenance ther-
apy, within the range of - 9 to +9%.
Response of stroke work index (Table 2). The cal-
culated stroke work index remainedsubstantiallyaugmented
(21 to 58%) during milrinone maintenance infusions. The
increases in stroke work index tended to be more modest
for the low dose regimen (about 20 to 30%) than for the
intermediate or high dose regimens (about 35 to 60% in-
creases).
Plasma milrinone concentrations (Fig. 5). The mean
plasma concentrationcurve, based on data from 10 patients
receiving the 50/0.5 regimen, is shown in Figure 5. The
maximal plasma concentrationduring the initial period was
370 ± 32 ng/ml and the average early period concentration
(5 minutes to 3 hours) was 229 ± 12 ng/rnl. Average mil-
rinone concentration was maintained at 215 ± II ng/ml
during day I and decreased slightly to average 179 ± 10
ng/ml during day 2. Paralleling the plasma concentrations
in these patients, the average cardiac index increased from
1.8 ± 0.1 liters/min per m2 at baseline to a maximum of
3.0 ± 0.1 and an early average of 2.4 ± 0.1 liters/min per
m2 between 5 minutes and 3 hours, to 2.3 ± 0.1 liters/min
per m2 between 6 and 24 hours (day 1), and to 2.3 ± 0.1
between 30 and 48 hours (day 2).
Adverse reactions (Table 4). The number of reported
adverse reactions was small, and the association with mil-
rinone often unclear. Ventricular and supraventricular ar-
rhythmias were the most frequently noted adverse experi-
ences, but usually did not require intervention. In ninepatients
with supraventricular arrhythmia (three with atrial fibrilla-
tion or flutter; six with atrhythmia of unspecified type) the
dose remained unchanged in seven, was reduced in two,
and was discontinued in none; three requiredadditionalanti-
arrhythmic therapy.
0/23 patients with ventricular arrhythmias . 15 had ven-
tricular ectopic activity and 8 had ventricular tachycardia
Table 4. Incidence of Adverse Reactions in 189 Patients*
Number of Patients (%)
*Table entries are the numberof patients who had at least one possible
drug-related adverse reaction. These data exclude reactions which had no
or remote relationsto the drug. Each patient is counted only once for each
adverse reaction. t Although thrombocytopenia occurred in four patients,
the investigator judged a possible relation to milrinone in only two of the
four.
Figure 5. Milrinone plasma concentration (mean :t SEM) versus
time for 10 patients receiving milrinone in doses of 50 JLg/kg per
10 min followed by 0.50 JLg/kg per min.
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Ventricular arrhythmias
Ventricular ectopic activity
Ventricular tachycardia
Supraventricular arrhythmias
Angina
Chest pain
Headache
Hypotension
Nausea
Diarrhea
Hypokalemia
Oliguria
Pulmonary edema
Somnolence
Thrombocytopenia
Tremor
23 (/2 .2)
15 (7.9)
8 (4.2)
9 (4.8)
1 (0 .5)
1 (0.5)
7 (3.7 )
4 (2.1)
1(0.5)
1(0.5)
2 (1.1 )
I (0.5)
1 (0.5)
1 (0.5 )
4 (2.2)t
1 (0.5)
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(nonsustained in 7). No change in milrinone regimen was
required in II of the patients experiencing ventricular ar-
rhythmia; the infusion dose was decreased in 3 patients and
discontinued in I. Antiarrhythmic therapywas administered
to four of the five patients who received therapeutic inter-
vention. Of the eight patients experiencing ventricular
tachycardia, the milrinone dose remained unchanged in fi ve,
was reduced in two and was discontinued in one. Antiar-
rhythmic therapy was administered to three of these eight
patients. Only one case of sustained ventricular tachycardia
occurred, requiring cardioversion; the arrhythmia was poly-
morphic and associated with a long QT interval.
The incidence of ventricular arrhythmias was similar for
doses of 0.25 to 0.50 /-Lg/kg per min (11 %); 4 (27%) of 15
patients receiving 0.75 /-Lg/kg per min had ventricular ar-
rhythmias . Although there was no significant relation be-
tween the milrinone dose regimen and the incidence of ven-
tricular arrhythmia, relatively few patients were studied at
the highest dose. Mean milrinone plasma concentration within
2 hours of occurrence of supraventricular or ventricular ar-
rhythmias were unremarkable: 256 and 265 ng/ml for the
two respective doses (median 244 and 253 ng/ml), Baseline
laboratory and clinical variables were also not consistently
predictive of arrhythmia and other adverse effects; hypo-
kalemiahad developedin one patientwith ventricular tachy-
cardia.
Analysis of laboratory data showed no consistent ab-
normalities or trends, although individual variations in sev-
eral variables were observed. These variations were gen-
erally believed by the investigator to represent single
anomalous values, departures not judged to be clinically
significant. Platelet counts decreased from above to below
100,000//-L1 (minimum 82,OOO/Jd) in only four cases with
subsequent recovery to baseline in I to 8 days. No clinically
significant changes in liver function tests considered to in-
dicate hepatotoxicity were observed.
Discussion
Summary of results. The results of this multicenter
intravenous milrinone study confirmthe acute hemodynamic
effects of milrinone demonstrated previously and also in-
dicate that the effect is maintained over the 48 hours of
infusion. Our results also suggested an effective mainte-
nance dose range (0.375 to 0.75 /-Lg/kg per min). An in-
effective maintenance dose was also defined (0.25 /-Lg/kg
per min). The relatively small numbers of patients given
the highest dose, together with variability in individual re-
sponse, precluded significant interdose comparisons within
the effectiverange (0.375 to 0.75 /-Lg/kg per min). However,
for stroke volume index and cardiac index, doses of 0.50
and 0.75 /-Lg/kg per min appeared equivalent and tended to
be slightly better than the dose of 0.375 1-Lg/kg per min
(Table 2). For pulmonary capillary wedgepressure and sys-
temic vascular resistance, little dosage effect was apparent.
For mean arterial pressure, doses of 0.375 and 0.50 were
equivalent and 0.75 /-Lg/kg per min tended to have greater
effects. These observations support the use of a loading
injection of 50 /-Lg/kg and a subsequent infusion dose of
0.375 to 0.75 /-Lg/kg per min, based on individual clinical
response. Safety evaluations suggest generallyexcellent tol-
erance; a 12% incidence of attendantventriculararrhythmias
(ectopic beats in 8%, runs in 4%) and a 5% incidence of
supraventricular arrhythmias were observed during milri-
none therapy, but the relation of most of these arrhythmias
to milrinone is difficult to assess from the present study.
Pharmacokinetic considerations. The rapid onset of
hemodynamic effects and the level of plasma milrinone
concentrations attained in this study are consistent with ob-
servations of others using shorter-term intravenous dosing.
Earlier studies in patients with heart failure have shown an
elimination half-life of 1.7 hours after single dose intra-
venous drug, with total body clearance of 0.10 to 0.15
liters/kg per h. and a volume of distribution of 0.3 to 0.4
liters/kg (48). Pharmacokinetics follow those predicted by
an open, two-compartment model. In patients receiving rel-
atively long (18 hour) infusions, steady state plasma con-
centrations averaged about 0.14 /-Lg/ml during dosing with
0.45 /-Lg/kg per min and 0.21 /-Lg/ml with 0.70 /-Lg/kg per
min (48), similar to but slightly less than those we observed
in selected patients (that is, 0.25 /-Lg/ml during 0.50 J.l-g/kg
per min infusions).
Other studies with intravenous milrinone . Our ob-
servations on the effects of 48 hour intravenous milrinone
infusions extend those of others using single or short-term
intravenous dosing (31- 34). LeJemtel ct al. (32) measured
the hemodynamic effects of an intravenous bolus of 25
/-Lg/kg in 26 patients. Cardiac index increased by 38%, pul-
monary capillary wedge pressure decreased by 28% and
right atrial pressure decreased by 40%. Benotti et al. (31)
performed a dose-ranging study of intravenous milrinone
injections in II patients with heart failure. Bolus doses of
12.5,25 , 50 and 75 /-Lg /kg were administered successively
at 6 hour intervals. Cardiac index increased progressively
with progressively larger doses (by 32, 35, 45 and 54%,
respectively), and correlated with increasing plasma drug
concentrations. Systemic vascular resistance decreased by
29 to 42% in a dose-dependent fashion. Decreases in pul-
monary capillary wedge pressure averaged about 40% with
the three lower doses, and about 55% after the 75 /-Lg/kg
dose. Hemodynamic effects were generally short-lived, re-
turning toward baseline within 2 hours after the lower dose
injections, and within about 3 hours after the highest dose.
Using a similar injection schedule in 27 patients, Baim et
al. (33) observed maximal reductions in left ventricular end-
diastolic pressure, pulmonary capillary wedge pressure and
right atrial pressure averaging 40% and increases in cardiac
index averaging 53%. Beneficial effects were maintained
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during 24 hour milrinone infusions (0.33 to 0.66 JLg/kg per
min). Thus, limited previous experience has suggested that
hemodynamic effects of acute intravenous milrinone may
be maintained for 12 to 24 hours by continuous infusion
regimens, but the present study tests the utility of various
doses of milrinone for periods of 48 hours. Our observations
suggest that sustained intravenous infusions maintain hemo-
dynamic effectiveness without development of tolerance or
toxicity for at least 48 hours.
Safety. The safety profile of intravenous milrinone for
infusion periods of 48 hours was acceptable. Adverse symp-
toms were rare and mild (for example, headache, flushing,
palpitation). The occurrence of arrhythmias during drug
therapy was also acceptable for this patient group with heart
failure; dose adjustment, drug discontinuation or additional
therapy was not required in most instances. Because the
occurrence of arrhythmias is common in these patients, the
possible relation of milrinone to arrhythmia occurrence re-
quires controlled observations, which have recently been
reported elsewhere for subsets of these patients (45,46). On
the basis of these observations, milrinone appears to have
modest proarrhythmic potential. Arrhythmogenicity of
standard and newer sympathomimetic amines appears to be
at least as high or higher than that of milrinone (51,52).
Thrombocytopenia was not problematic (I to 2%). No plate-
let counts <82,000/JLl were observed and in only four cases
did counts fall transiently to < 100,000/JLI. Evaluation of
occasional elevations in liver function tests is difficult in
the setting of congestive heart failure. However, those ob-
served in the present study appeared to represent single
sporadic variations and were not of clinical importance.
Proposal for clinical use of intravenous milrinone.
The observations noted from the previous and present stud-
ies suggest that milrinone may be a useful agent when acute
and short-term intravenous inotropic therapy of heart failure
is indicated. Although the ultimate value of long-term oral
therapy with inotropic versus alternative approaches remains
to be fully explored, the utility of short-term intravenous
therapy is more readily apparent. When reversible com-
ponents of congestive heart failure such as postoperative
status, acute ischemic events, volume, electrolyte or acid-
base imbalance and drug-induced heart failure (for example,
calcium channel blocker or beta-blocker therapy) are present
and are inadequately responsive to standard therapeutic ma-
neuvers, intravenous milrinone therapy may provide a ben-
eficial hemodynamic effect. Amrinone, already an approved
drug for intravenous use, has similar hemodynamic effects
and presumed mechanisms of action (21-24,30). However,
milrinone has the advantage of being better tolerated as an
oral drug, allowing for continued therapy in patients re-
quiring longer-term inotropic support (25-35,50). At pres-
ent, the efficacy and safety of long-term oral milrinone are
being evaluated in three blinded, placebo-controlled mul-
ticenter trials.
Conclusions. On the basis of the present and previous
observations, milrinone is likely to be a useful agent for
acute and longer-term intravenous support of cardiovascular
function when heart failure is unresponsive to conventional
therapy with diuretics or vasodilators. Because patients treated
in the present study generally had stable although advanced
congestive heart failure, additional studies are indicated in
those with congestive heart failure from more acute causes.
We thank Marian Bartholomew and Shari Bailey for typing the manuscript.
Appendix
Participating Institutions and Investigators
Clinical Centers
The Albany Medical College, Albany, NY. Principal Investigator:
Joseph T. Doyle, MD; Associate Investigators: Steven A. Fein, MD,
Edward M. Wright. MD. Robert J. Parkes, MD, Anne Keane, RPA-C.
Albert Einstein College of Medicine, Bronx, NY. Co-Investigators:
Edmund H. Sonnenblick, MD, Thierry H. LeJemtel, MD.
Cleveland Chnic Foundation, Cleveland, OH. Co-Investigators:
Gustavo Rincon, MD, Khosrow Dorosti, MD: Associate Investigators:
John Ellis, MD.
Hahnemann University, Philadelphia, PA. Principal Investigator:
MarieH J. Likoff, MD.
Beth Israel Hospital, Boston, MA. Principal Investigator: Donald S.
Bairn, MD; Associate Investigators: E. SCOII Monrad, MD. Harton Smith.
MD, Alyce S. Lanoue, RN, MS.
Brigham and Women's Hospital, Boston, MA. Principal Investi-
gator: Wilson S. Colucci, MD; Associate Investigators: Eugene Braunwald,
MD, Richard F. Wright, MD, Malcolm Arnold, MD, Michael A. Fifer.
MD, Brian Jaski, MD.
. Medical College of Virginia, Richmond, VA. Principal Investigator:
Michael Hess, MD: Associate Investigators: George W. Vetrovec, MD,
FACC, Andrea Hastillo, MD, James A. Thompson, MD.
New England Deaconess Hospital, Boston, MA. Principal Investi-
gator: Edward Kosinski, MD; Associate Investigator: Eric Eichhorn, MD.
University of North Carolina at Chapel Hill, Chapel Hill, NC. Co-
Investigators: Kirwood Adams, MD, Leonard S. Gelles, MD: Associate
Investigator: Barbara Berka, MD.
University of Pittsburgh School of Medicine, Pittsburgh, PA, Prin-
cipal Investigator: Barry F. Uretsky, MD; Associate Investigators: Thomas
Generalovich, MD, Sudhakar P. Reddy, MD.
Stantord University Medical Center, Stanford, CA. Co-Investiga-
tors: Edwin L. Alderman, MD. John Schroeder, MD: Associate Investi-
gator: Michael Fowler. MD; Study Coordinator: M. Shelley McCrory, RN.
University of Texas Health Science Center, Houston, TX. Principal
Investigator: Richard A. Goldstein. MD; Associate Investigators: Stephen
A. Geraci. MD, Gerald V. Naccarelli, MD. Elayne L. Gray, RN, BSN,
Anne H. Dougherty, MD. Charles H. Hicks, MD. Robert Rinkenberger.
MD.
University of Utah Medical School, LDS Hospital, Salt Lake City,
UT. Principal Investigator: Jeffrey L. Anderson. MD; Associate Investi-
gators: Jack C. Askins, MD, Edward M. Gilbert, MD; Study Coordinator:
Joan R. Lutz, RN.
Sterling-Winthrop Research Institute (Coordinating Sponsor). David
P. Benziger, PhD, Susan FitzPatrick, Jack C. Jacobsen, Ronald P. Ker-
shner, PhD. Conrad Krebs, MD, Carol A. Luczkowec, Maria Montenaro,
Ronald M. Stroshane, PhD, P. K. Tandon, PhD, Louise H. Walton.
Richard P. Schwarz, Jr, PhD.
Publicanon Committee. Chairman: Jeffrey L. Anderson, MD, Uni-
versity of Utah Medical School, Salt Lake City, Utah. Members: Donald
S. Bairn, MD, Harvard University Medical School, Boston, MA; Steven
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A. Fein. MD. Albany Medical College. Albany. NY: Richard A. Gold-
stein. MD. University of Texas Health Sciences Center. Houston. TX;
Thierry H. Le.lemtel, MD. Albert Einstein College of Medicine. Bronx.
NY; Mariell J. Likoff, MD. Hahnemann University. Philadelphia. PA.
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